CA2634094A1 - Formulations pharmaceutiques de fenofibrate ayant une biodisponibilite amelioree - Google Patents

Formulations pharmaceutiques de fenofibrate ayant une biodisponibilite amelioree Download PDF

Info

Publication number
CA2634094A1
CA2634094A1 CA002634094A CA2634094A CA2634094A1 CA 2634094 A1 CA2634094 A1 CA 2634094A1 CA 002634094 A CA002634094 A CA 002634094A CA 2634094 A CA2634094 A CA 2634094A CA 2634094 A1 CA2634094 A1 CA 2634094A1
Authority
CA
Canada
Prior art keywords
fenofibrate
dosage form
weight
oral dosage
solid oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002634094A
Other languages
English (en)
Inventor
E. Itzhak Lerner
Vered Rosenberger
Moshe Flashner-Barak
Anna Drabkin
Naomi Moldavski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2634094A1 publication Critical patent/CA2634094A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
CA002634094A 2005-12-28 2005-12-28 Formulations pharmaceutiques de fenofibrate ayant une biodisponibilite amelioree Abandoned CA2634094A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2005/047346 WO2007075171A1 (fr) 2005-12-28 2005-12-28 Formulations pharmaceutiques de fénofibrate ayant une biodisponibilité améliorée

Publications (1)

Publication Number Publication Date
CA2634094A1 true CA2634094A1 (fr) 2007-07-05

Family

ID=36499668

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002634094A Abandoned CA2634094A1 (fr) 2005-12-28 2005-12-28 Formulations pharmaceutiques de fenofibrate ayant une biodisponibilite amelioree

Country Status (7)

Country Link
JP (1) JP2009522258A (fr)
CN (1) CN101351191A (fr)
BR (1) BRPI0520821A2 (fr)
CA (1) CA2634094A1 (fr)
IL (1) IL192230A0 (fr)
MX (1) MX2008008589A (fr)
WO (1) WO2007075171A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011029181A1 (fr) * 2009-09-09 2011-03-17 Bernard Charles Sherman Compositions de fénofibrate de choline à libération retardée
JP6752140B2 (ja) * 2013-03-14 2020-09-09 アイミューン セラピューティクス,インコーポレイテッド 経口脱感作のための落花生処方物の製造
KR101850119B1 (ko) 2015-11-11 2018-04-20 제이투에이치바이오텍 (주) 생체이용률이 향상된 신규한 페노피브르산 전구약물
AU2020276213A1 (en) 2019-05-10 2021-10-28 Société des Produits Nestlé S.A. Methods for improving the quality of life of a patient with a peanut allergy
CN112618511A (zh) * 2020-12-31 2021-04-09 辰欣药业股份有限公司 一种非诺贝特胶囊的处方组成及制备工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6368622B2 (en) * 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
AU6294501A (en) * 2000-09-20 2002-04-02 Rtp Pharma Inc Spray drying process and compositions of fenofibrate
EP2087882A1 (fr) * 2002-03-26 2009-08-12 Teva Pharmaceutical Industries Ltd. Microparticules de médicament
KR20060085682A (ko) * 2003-10-10 2006-07-27 라이프사이클 파마 에이/에스 피브레이트 및 스타틴을 함유하는 고형 제제
JP5069001B2 (ja) * 2003-10-10 2012-11-07 ベロクシス ファーマシューティカルズ エー/エス フィブラートを含む固体投与形態

Also Published As

Publication number Publication date
JP2009522258A (ja) 2009-06-11
IL192230A0 (en) 2008-12-29
WO2007075171A1 (fr) 2007-07-05
MX2008008589A (es) 2009-02-25
BRPI0520821A2 (pt) 2009-06-30
CN101351191A (zh) 2009-01-21

Similar Documents

Publication Publication Date Title
US20170319538A1 (en) Solid pharmaceutical compositions containing benzofuran derivatives
US8663703B2 (en) Drug microparticles, processes of preparing them and a drug delivery vehicle comprising them
EP2442799B1 (fr) Composition pharmaceutique solide comprenant du rivaroxaban
US7939104B2 (en) Solubility of hydrophobic drugs with a compound having a carboxylic acid moiety
JP5560188B2 (ja) 水分散性の乾いた形態の医薬品の新規製造方法およびそれに伴い得られる医薬組成物
US6919378B2 (en) Pharmaceutical solutions of modafinil compounds
WO2006107411A2 (fr) Preparations ameliorees a base de fenofibrate
US20070148233A1 (en) Pharmaceutical formulations of fenofibrate having improved bioavailability
JP2008534584A (ja) フェノフィブラート含有メントール又はpeg/ポロキサマー混合物の改良製剤
CA2634094A1 (fr) Formulations pharmaceutiques de fenofibrate ayant une biodisponibilite amelioree
WO2008104852A2 (fr) Compositions pharmaceutiques comprenant un adsorbate de fénofibrate
EP1803441B1 (fr) Formulation pharmaceutique comprenant du fénofibrate ayant une biodisponibilité ameliorée
US20220273652A1 (en) Pharmaceutical composition comprising hmg-coa reductase inhibitors and fenofibrate
JP4510156B2 (ja) 難溶性薬剤物質を含有する医薬製剤
KR20080087845A (ko) 개선된 생체이용률을 갖는 페노피브레이트의 약학적 제제
WO2024084446A1 (fr) Composition de fénofibrate comprenant des produits chimiques solubles dans l'eau et son procédé de production
WO2007064084A1 (fr) Granules contenant du pranlukast et leurs procedes de preparation

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued